bcl-2 Protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells
- 1 February 1996
- journal article
- Published by Elsevier in Leukemia Research
- Vol. 20 (2) , 101-107
- https://doi.org/10.1016/0145-2126(95)00103-4
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation.Proceedings of the National Academy of Sciences, 1994
- Cytostatic and cytotoxic activity of sex steroids against human leukemia cell linesCancer Letters, 1994
- Reversal of Chemoresistance of Lymphoma Cells by Antisense-Mediated Reduction ofbcl-2 Gene ExpressionAntisense Research and Development, 1994
- Bcl-2 and the regulation of programmed cell deathThe Journal of cell biology, 1994
- 1,25-Dihydroxyvitamin D3 Protects HL60 Cells against Apoptosis but Down-regulates the Expression of the bcl-2 GeneExperimental Cell Research, 1993
- WAF1, a potential mediator of p53 tumor suppressionCell, 1993
- Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell deathCell, 1993
- bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell deathCell, 1993
- Internucleosomal DNA fragmentation during phorbol ester-induced monocytic differentiation and G0/G1 arrest.Journal of Clinical Investigation, 1992
- Use of the polymerase chain reaction in the quantitation of MDR-1 gene expressionBiochemistry, 1990